ROCHESTER, N.Y., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Vaccinex, Inc., a privately-held clinical-stage biotechnology company engaged in the development of therapeutic monoclonal antibodies to treat ...

ROCHESTER, N.Y., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating ...

ROCHESTER, N.Y., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating ...

Expect to complete patient enrollment in the randomized Phase 1/2a SIGNAL-AD Alzheimer’s study in April 2023 with topline data anticipated mid-2024 Completed enrollment of 36 patients required for a ...

ROCHESTER, N.Y., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Vaccinex (VCNX), Inc. , a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease ...

ROCHESTER, N.Y., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease and cancer ...

Vaccinex announced the immediate exercise of outstanding warrants to purchase 1,067,492 shares for $5.36 per share. The exercise of these warrants led to the issuance of 827,483 shares and the ...

Vaccinex shares are trading lower by 7.1%Thursday morning. The company announced a 1-for-14 reverse stock split. Live on Wednesday: Historic Summer Setup: 3 "Power Patterns" Triggering in the next 75 ...

Presentation title: Neoadjuvant biomarker trial of pepinemab to enhance nivolumab or ipilimumab activity in resectable head and neck cancer. Abstract 103. Time: 9:45-11:15 AM CST/10:45 AM – 12:15 PM ...

Fintel reports that Fcmi Parent has filed a 13D/A form with the SEC disclosing ownership of 23.49MM shares of Vaccinex Inc (VCNX). This represents 42.8% of the company. In their previous filing dated ...